Skip to main content
. 2013 Sep 25;8(9):e75366. doi: 10.1371/journal.pone.0075366

Figure 3. Pre-validation of serum sCD14 as a biomarker for predicting the recurrence of breast invasive ductal carcinoma with LN+ER/PR-Her2+.

Figure 3

(A) Comparison of the level of serum sCD14 in relapse and relapse-free patients of breast cancer with LN+ER/PR-Her2+ status. The level of serum sCD14 was significantly lower in the patients with recurrence than those without recurrence (p<0.001). (B) The receiver operating characteristics (ROC) curve of serum sCD14. The AUC was 0.833 (95% CI, 0.742 to 0.920).